Recirculation of chronic lymphocytic leukemia (CLL) cells between the peripheral blood and lymphoid niches plays a critical role in disease pathophysiology, and inhibiting this process is one of the major mechanisms of action for B-cell receptor (BCR) inhibitors such as ibrutinib and idelalisib. Migration is a complex process guided by chemokine receptors and integrins. However, it remains largely unknown how CLL cells integrate multiple migratory signals while balancing survival in the peripheral blood and the decision to return to immune niches. Our study provided evidence that CXCR4/CD5 intraclonal subpopulations can be used to study the regulation of migration of CLL cells. We performed RNA profiling of CXCR4dimCD5bright vs CXCR4brightCD5dim CLL cells and identified differential expression of dozens of molecules with a putative function in cell migration. GRB2-associated binding protein 1 (GAB1) positively regulated CLL cell homing capacity of CXCR4brightCD5dim cells. Gradual GAB1 accumulation in CLL cells outside immune niches was mediated by FoxO1-induced transcriptional GAB1 activation. Upregulation of GAB1 also played an important role in maintaining basal phosphatidylinositol 3-kinase (PI3K) activity and the "tonic" AKT phosphorylation required to sustain the survival of resting CLL B cells. This finding is important during ibrutinib therapy, because CLL cells induce the FoxO1-GAB1-pAKT axis, which represents an adaptation mechanism to the inability to home to immune niches. We have demonstrated that GAB1 can be targeted therapeutically by novel GAB1 inhibitors, alone or in combination with BTK inhibition. GAB1 inhibitors induce CLL cell apoptosis, impair cell migration, inhibit tonic or BCR-induced AKT phosphorylation, and block compensatory AKT activity during ibrutinib therapy.

Centre for Neuroscience CEITEC Masaryk University Brno Czech Republic

Department of Experimental Therapeutics The University of Texas MD Anderson Cancer Center Houston TX

Department of Histology and Embryology Faculty of Medicine and

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Pathology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Experimental Biophotonics CEITEC University of Technology Brno Czech Republic

Genomics Core Facility EMBL Heidelberg Germany; and

Molecular Medicine CEITEC Masaryk University and

Zobrazit více v PubMed

Calissano C, Damle RN, Marsilio S, et al. . Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med. 2011;17(11-12):1374-1382. PubMed PMC

Pavlasova G, Borsky M, Seda V, et al. . Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016;128(12):1609-1613. PubMed PMC

Pavlasova G, Borsky M, Svobodova V, et al. . Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. Leukemia. 2018;32(9):2028-2031. PubMed

Herndon TM, Chen SS, Saba NS, et al. . Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leukemia. 2017;31(6):1340-1347. PubMed PMC

Bartholdy BA, Wang X, Yan XJ, et al. . CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation. Blood Adv. 2020;4(5):893-905. PubMed PMC

Chen SS, Chang BY, Chang S, et al. . BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30(4):833-843. PubMed PMC

Sharma S, Pavlasova GM, Seda V, et al. . miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors [published online ahead of print 10 November 2020]. Blood. doi:10.1182/blood.2020005627. PubMed PMC

Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1996;92(1):97-103. PubMed

Herishanu Y, Pérez-Galán P, Liu D, et al. . The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2): 563-574. PubMed PMC

Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell’Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96(8):2655-2663. PubMed

Mraz M, Zent CS, Church AK, et al. . Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol. 2011;155(1):53-64. PubMed PMC

Byrd JC, Furman RR, Coutre SE, et al. . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42. PubMed PMC

Furman RR, Sharman JP, Coutre SE, et al. . Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007. PubMed PMC

Ponader S, Chen SS, Buggy JJ, et al. . The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182-1189. PubMed PMC

Arbonés ML, Ord DC, Ley K, et al. . Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity. 1994;1(4):247-260. PubMed

Lafouresse F, Bellard E, Laurent C, et al. . L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in vivo. Blood. 2015;126(11):1336-1345. PubMed

Till KJ, Lin K, Zuzel M, Cawley JC. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood. 2002;99(8):2977-2984. PubMed

Tissino E, Benedetti D, Herman SEM, et al. . Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med. 2018; 215(2):681-697. PubMed PMC

Ghobrial IM, Bone ND, Stenson MJ, et al. . Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Mayo Clin Proc. 2004;79(3):318-325. PubMed

Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999; 94(11):3658-3667. PubMed

Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007;110(9):3316-3325. PubMed

Niemann CU, Herman SE, Maric I, et al. . Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib–Findings from an Investigator-Initiated Phase II Study. Clin Cancer Res. 2016;22(7):1572-1582. PubMed PMC

Sivina M, Xiao L, Kim E, et al. . CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia [published online ahead of print 21 Oct 2020]. Leukemia. doi:10.1038/s41375-020-01063-7 PubMed PMC

Ringshausen I, Schneller F, Bogner C, et al. . Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood. 2002;100(10):3741-3748. PubMed

Srinivasan L, Sasaki Y, Calado DP, et al. . PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009;139(3):573-586. PubMed PMC

Zhuang J, Hawkins SF, Glenn MA, et al. . Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica. 2010;95(1):110-118. PubMed PMC

Gobessi S, Laurenti L, Longo PG, et al. . Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia. 2009;23(4): 686-697. PubMed

Herman SE, Sun X, McAuley EM, et al. . Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia. 2013;27(12):2311-2321. PubMed PMC

Lam KP, Kühn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997;90(6):1073-1083. PubMed

Ondrisova L, Mraz M. Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies. Front Oncol. 2020;10:591577. PubMed PMC

Sang H, Li T, Li H, Liu J. Down-regulation of Gab1 inhibits cell proliferation and migration in hilar cholangiocarcinoma. PLoS One. 2013;8(11):e81347. PubMed PMC

Vasyutina E, Stebler J, Brand-Saberi B, Schulz S, Raz E, Birchmeier C. CXCR4 and Gab1 cooperate to control the development of migrating muscle progenitor cells. Genes Dev. 2005;19(18):2187-2198. PubMed PMC

Ingham RJ, Holgado-Madruga M, Siu C, Wong AJ, Gold MR. The Gab1 protein is a docking site for multiple proteins involved in signaling by the B cell antigen receptor. J Biol Chem. 1998;273(46):30630-30637. PubMed

Ingham RJ, Santos L, Dang-Lawson M, et al. . The Gab1 docking protein links the b cell antigen receptor to the phosphatidylinositol 3-kinase/Akt signaling pathway and to the SHP2 tyrosine phosphatase. J Biol Chem. 2001;276(15):12257-12265. PubMed

Mraz M, Chen L, Rassenti LZ, et al. . miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood. 2014;124(1):84-95. PubMed PMC

Meng S, Chen Z, Munoz-Antonia T, Wu J. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor. Biochem J. 2005;391(pt 1):143-151. PubMed PMC

Cai T, Nishida K, Hirano T, Khavari PA. Gab1 and SHP-2 promote Ras/MAPK regulation of epidermal growth and differentiation. J Cell Biol. 2002;159(1):103-112. PubMed PMC

Takahashi-Tezuka M, Yoshida Y, Fukada T, et al. . Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol Cell Biol. 1998;18(7):4109-4117. PubMed PMC

Holgado-Madruga M, Emlet DR, Moscatello DK, Godwin AK, Wong AJA. A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature. 1996;379 (6565):560-564. PubMed

Sakkab D, Lewitzky M, Posern G, et al. . Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL. J Biol Chem. 2000;275(15):10772-10778. PubMed

Hertlein E, Beckwith KA, Lozanski G, et al. . Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease. PLoS One. 2013;8(10):e76607. PubMed PMC

Shultz LD, Lyons BL, Burzenski LM, et al. . Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174(10):6477-6489. PubMed

Chen L, Du-Cuny L, Moses S, et al. . Novel inhibitors induce large conformational changes of GAB1 pleckstrin homology domain and kill breast cancer cells. PLOS Comput Biol. 2015;11(1):e1004021. PubMed PMC

Cerna K, Oppelt J, Chochola V, et al. . MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. Leukemia. 2019;33(2):403-414. PubMed

Chen L, Widhopf G, Huynh L, et al. . Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100(13):4609-4614. PubMed

Bagnara D, Kaufman MS, Calissano C, et al. . A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood. 2011;117(20):5463-5472. PubMed PMC

Ashburner M, Ball CA, Blake JA, et al. . The Gene Ontology Consortium . Gene ontology: tool for the unification of biology. Nat Genet. 2000;25(1):25-29. PubMed PMC

Lambert SA, Jolma A, Campitelli LF, et al. . The Human Transcription Factors [published correction appears in Cell. 2018;175(2):598-599]. Cell. 2018;172(4):650-665. PubMed

Kerdiles YM, Beisner DR, Tinoco R, et al. . Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat Immunol. 2009;10(2):176-184. PubMed PMC

Dengler HS, Baracho GV, Omori SA, et al. . Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol. 2008;9(12):1388-1398. PubMed PMC

Sander S, Chu VT, Yasuda T, et al. . PI3 Kinase and FOXO1 Transcription Factor Activity Differentially Control B Cells in the Germinal Center Light and Dark Zones. Immunity. 2015;43(6):1075-1086. PubMed

Kabrani E, Chu VT, Tasouri E, et al. . Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells. Blood. 2018;132(25):2670-2683. PubMed

Beekman R, Chapaprieta V, Russiñol N, et al. . The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat Med. 2018;24(6):868-880. PubMed PMC

Pyrzynska B, Dwojak M, Zerrouqi A, et al. . FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. OncoImmunology. 2018;7(5):e1423183. PubMed PMC

Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011;1813(11):1978-1986. PubMed

Deng Y, Wang F, Hughes T, Yu J. FOXOs in cancer immunity: Knowns and unknowns. Semin Cancer Biol. 2018;50:53-64. PubMed PMC

Byrd JC, Brown JR, O’Brien S, et al. . RESONATE Investigators . Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223. PubMed PMC

Cervantes-Gomez F, Kumar Patel V, Bose P, Keating MJ, Gandhi V. Decrease in total protein level of Bruton’s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Leukemia. 2016;30(8):1803-1804. PubMed PMC

Cui B, Chen L, Zhang S, et al. . MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014;124(4):546-554. PubMed PMC

Ali AY, Wu X, Eissa N, et al. . Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration. Leukemia. 2018;32(9):1958-1969. PubMed PMC

Roy NH, MacKay JL, Robertson TF, Hammer DA, Burkhardt JK. Crk adaptor proteins mediate actin-dependent T cell migration and mechanosensing induced by the integrin LFA-1. Sci Signal. 2018;11(560):eaat3178. PubMed PMC

Thomas MS, Mitchell JS, DeNucci CC, Martin AL, Shimizu Y. The p110gamma isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites. J Leukoc Biol. 2008;84(3):814-823. PubMed PMC

Martin AL, Schwartz MD, Jameson SC, Shimizu Y. Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase. J Immunol. 2008;180(4):2081-2088. PubMed

Zhang X, Gan L, Pan H, et al. . Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem. 2002;277(47):45276-45284. PubMed

Brunet A, Bonni A, Zigmond MJ, et al. . Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96(6):857-868. PubMed

Xiao W, Dong G, Pacios S, et al. . FOXO1 deletion reduces dendritic cell function and enhances susceptibility to periodontitis. Am J Pathol. 2015;185(4):1085-1093. PubMed PMC

Trinh DL, Scott DW, Morin RD, et al. . Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121(18):3666-3674. PubMed PMC

Szydlowski M, Kiliszek P, Sewastianik T, et al. . FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. Blood. 2016;127(6):739-748. PubMed

Aasrum M, Ødegård J, Sandnes D, Christoffersen T. The involvement of the docking protein Gab1 in mitogenic signalling induced by EGF and HGF in rat hepatocytes. Biochim Biophys Acta. 2013;1833(12):3286-3294. PubMed

Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice

FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia

Computational Design of Pore-Forming Peptides with Potent Antimicrobial and Anticancer Activities

Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing

Towards a Better Characterisation of Leukemic Cells in Chronic Lymphocytic Leukaemia: Cell-Size Heterogeneity Reflects Their Activation Status and Migratory Abilities